GHK-Cu vs Semax
Head-to-head comparison of GHK-Cu and Semax for research applications. Both peptides are studied for various research applications, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ghk Cu | Semax |
|---|---|---|
| Category | Skin & Tissue Repair | Nootropic / Neuroprotective |
| Mechanism | GHK-Cu chelates copper(II) ions via its histidine residue and delivers bioavailable copper directly to cells, preventing free copper oxidative damage. | Semax is a brain-selective heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro, MW ~813.88 g/mol) that crosses the blood-brain barrier via intranasal absorption. |
| Evidence Rating | F — No Regulatory Activity | D — Preclinical |
| Clinical Status | Available in cosmetic formulations; no drug approval | Approved in Russia and Ukraine for stroke and cognitive disorders; not approved elsewhere |
| Safety Profile | Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520); Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin | Generally favorable safety profile with uncommon mild side effects and no dependence potential; No significant hormonal effects despite ACTH-fragment origin — brain-selective mechanism reduces systemic side effects |
| Route | Subcutaneous, Topical (cream/serum), or Intradermal (microneedling) | Intranasal (preferred) or Subcutaneous |
| Dose Range | SC: 50–200 mcg/day; Topical: 1–4% cream or serum applied to target area | Intranasal: 200–600 mcg per nostril, 2–3x daily; SC: 200–600 mcg daily |
| Frequency | SC: Once daily; Topical: 1–2x daily | 2–3 times daily (intranasal); once daily (SC) |
| Molecular Weight | ~403.9 g/mol | ~813.9 g/mol |
| Half-Life | ~30 minutes plasma | ~3–5 minutes; intranasal extends effective duration |
Overview
GHK-Cu and Semax are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
GHK-Cu — Mechanism & Evidence
GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. First discovered by Dr. Loren Pickart in 1973, plasma levels average 200 ng/mL at age 20 but decline to ~80 ng/mL by age 60. It has been extensively studied for wound healing, collagen synthesis, skin regeneration, and gene modulation, with decades of cosmetic use and a broad safety profile. Molecular weight is approximately 340 g/mol (as the copper complex), with the formula C14H24N6O4Cu.
Key claims: Improves skin firmness and elasticity; Promotes wound healing; Reduces fine lines and wrinkles.
Semax — Mechanism & Evidence
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from adrenocorticotropic hormone (ACTH) fragment 4-10, with an added Pro-Gly-Pro sequence for metabolic stability. Molecular weight is approximately 813.88 g/mol (formula C37H51N9O10S). Discovered in Russia during the 1980s as part of government-funded neuropeptide research, it is approved in Russia and Ukraine for the treatment of ischemic stroke, cognitive disorders, encephalopathy, and optic nerve atrophy. Despite its ACTH origin, Semax does not activate adrenal corticosteroid production, acting selectively on brain-specific pathways.
Key claims: Neuroprotective in stroke; Enhances memory and cognitive function; Increases BDNF levels.
Shared Research Applications
These peptides target different research areas. GHK-Cu focuses on Skin Health, Anti-Aging, Wound Healing, while Semax targets Cognitive Enhancement.
Safety Considerations
GHK-Cu: Safety profile is excellent with minimal side effects reported in decades of cosmetic use and clinical research (PMID: 29986520) Topical forms are generally well-tolerated; mild skin irritation rare and typically limited to very sensitive skin Injectable forms: mild injection site reactions, lightheadedness, nausea, flu-like symptoms possible; rotate injection sites to reduce local irritation
Semax: Generally favorable safety profile with uncommon mild side effects and no dependence potential No significant hormonal effects despite ACTH-fragment origin — brain-selective mechanism reduces systemic side effects Administered intranasally — mild nasal irritation possible; proper spray technique recommended
Shop Research Peptides
GHK-Cu 50mg
50mg
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
KPV 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
GHK-Cu in Research: Reconstitution, Stability, and Handling Guide
This guide covers the essentials of working with GHK-Cu in a research setting, from reconstitution math and solvent choice to stability and purity considerations. Learn how to handle copper peptides correctly and what to verify before starting a study.
FDA Panel Recommends Semax for Pharmacy Compounding: Manufacturing News
An FDA advisory panel has recommended the peptide Semax be added to the pharmacy compounding list, a move that could expand access for researchers. The decision comes amid broader discussions about peptide regulation, including a vote against emideltide. This semax manufacturing news highlights shifting industry dynamics.
GHK-Cu and Hair Follicle Growth: A Review of Copper Peptide Dermatological Research
Explore the preclinical evidence on GHK-Cu for hair follicle growth, including proposed mechanisms and research limitations.